ATYR
Price
$5.38
Change
+$0.03 (+0.56%)
Updated
Jun 6 closing price
Capitalization
474.39M
66 days until earnings call
DRUG
Price
$27.61
Change
-$0.20 (-0.72%)
Updated
Jun 6 closing price
Capitalization
195.2M
Interact to see
Advertisement

ATYR vs DRUG

Header iconATYR vs DRUG Comparison
Open Charts ATYR vs DRUGBanner chart's image
aTyr Pharma
Price$5.38
Change+$0.03 (+0.56%)
Volume$2.6M
Capitalization474.39M
Bright Minds Biosciences
Price$27.61
Change-$0.20 (-0.72%)
Volume$20K
Capitalization195.2M
ATYR vs DRUG Comparison Chart
Loading...
ATYR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DRUG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATYR vs. DRUG commentary
Jun 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATYR is a Buy and DRUG is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 09, 2025
Stock price -- (ATYR: $4.20 vs. DRUG: $27.35)
Brand notoriety: ATYR and DRUG are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATYR: 175% vs. DRUG: 82%
Market capitalization -- ATYR: $474.39M vs. DRUG: $195.2M
ATYR [@Biotechnology] is valued at $474.39M. DRUG’s [@Biotechnology] market capitalization is $195.2M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATYR’s FA Score shows that 0 FA rating(s) are green whileDRUG’s FA Score has 0 green FA rating(s).

  • ATYR’s FA Score: 0 green, 5 red.
  • DRUG’s FA Score: 0 green, 5 red.
According to our system of comparison, DRUG is a better buy in the long-term than ATYR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATYR’s TA Score shows that 6 TA indicator(s) are bullish while DRUG’s TA Score has 5 bullish TA indicator(s).

  • ATYR’s TA Score: 6 bullish, 4 bearish.
  • DRUG’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both ATYR and DRUG are a good buy in the short-term.

Price Growth

ATYR (@Biotechnology) experienced а +12.00% price change this week, while DRUG (@Biotechnology) price change was -10.12% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

ATYR is expected to report earnings on Aug 13, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATYR($474M) has a higher market cap than DRUG($195M). ATYR YTD gains are higher at: 16.022 vs. DRUG (-24.070). DRUG has higher annual earnings (EBITDA): -2.67M vs. ATYR (-66.37M). ATYR has more cash in the bank: 72.1M vs. DRUG (57.9M). DRUG has less debt than ATYR: DRUG (183K) vs ATYR (13.3M). ATYR has higher revenues than DRUG: ATYR (235K) vs DRUG (0).
ATYRDRUGATYR / DRUG
Capitalization474M195M243%
EBITDA-66.37M-2.67M2,484%
Gain YTD16.022-24.070-67%
P/E RatioN/AN/A-
Revenue235K0-
Total Cash72.1M57.9M125%
Total Debt13.3M183K7,268%
FUNDAMENTALS RATINGS
ATYR: Fundamental Ratings
ATYR
OUTLOOK RATING
1..100
15
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
39
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ATYRDRUG
RSI
ODDS (%)
Bearish Trend 12 days ago
88%
Bullish Trend 12 days ago
69%
Stochastic
ODDS (%)
Bearish Trend 12 days ago
85%
Bullish Trend 12 days ago
87%
Momentum
ODDS (%)
Bullish Trend 12 days ago
80%
Bearish Trend 12 days ago
88%
MACD
ODDS (%)
Bullish Trend 12 days ago
75%
Bearish Trend 12 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 12 days ago
80%
Bearish Trend 12 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 12 days ago
84%
Bearish Trend 12 days ago
89%
Advances
ODDS (%)
Bullish Trend 12 days ago
79%
Bullish Trend 24 days ago
85%
Declines
ODDS (%)
Bearish Trend 25 days ago
84%
Bearish Trend 12 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 12 days ago
84%
Bullish Trend 12 days ago
81%
Aroon
ODDS (%)
Bullish Trend 12 days ago
87%
Bullish Trend 12 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ATYR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DRUG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

ATYR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATYR has been loosely correlated with MGTX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ATYR jumps, then MGTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATYR
1D Price
Change %
ATYR100%
+8.53%
MGTX - ATYR
44%
Loosely correlated
+0.20%
NTLA - ATYR
40%
Loosely correlated
+3.59%
SLDB - ATYR
38%
Loosely correlated
+7.24%
AURA - ATYR
38%
Loosely correlated
+0.17%
ERAS - ATYR
37%
Loosely correlated
+1.85%
More

DRUG and

Correlation & Price change

A.I.dvisor indicates that over the last year, DRUG has been loosely correlated with PHMMF. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if DRUG jumps, then PHMMF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DRUG
1D Price
Change %
DRUG100%
-0.33%
PHMMF - DRUG
44%
Loosely correlated
N/A
TVGN - DRUG
31%
Poorly correlated
+1.55%
ATYR - DRUG
31%
Poorly correlated
+8.53%
SEER - DRUG
29%
Poorly correlated
+1.53%
PHGUF - DRUG
28%
Poorly correlated
N/A
More